EVH — Stock Film
STOCK FILMSCENE 1/11EVH · $4.74
Stock Expert AI presents
EVH
Evolent Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Evolent Health, Inc. A quick introduction.

On the stock market since 2015, it operates in the world of health and science. It has 4,200 employees. Now — the numbers.

on the stock market since 2015
4,200 employees
$474.7M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.3.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 20% a year over the last 4 years. Red columns mark years that ended in a loss.

$908M
2021
$1.4B
2022
$2B
2023
$2.6B
2024
$1.9B
2025
In the vault right now:
$0
DEBT: $989.7M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
46
weak

Clearly below the class average.

FINANCIAL STRENGTH
57
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
58
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
45
weak

Clearly below the class average.

PRICE MOMENTUM
56
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 12% a year on average.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 25 buys and 13 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $5.8323% above today’s price.

1
THE RISKS · 1/2
The losses continue

A loss of $534.5M against $1.9B in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, EVH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: EVH has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (58/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film